CNS - Cohen & Steers, Inc. 0 WATCHERS

RVPH Might Be the Sleeper Play Nobody’s Talking About Not financial advice — just what I’m seeing. RVPH has been way too quiet for a stock sitting this close to an FDA submission. Most under-$1 biotechs are pre-clinical junk. This one actually finished Phase 3 with solid safety and promising …

BDTX Phase 2 update shorts in trouble upvote post. Black Diamond Therapeutics (BDTX) just released preliminary Phase 2 data for silevertinib in 1L NSCLC — and it's way stronger than expected: 🔥 Clinical Results (Headline Numbers) 60% ORR across 35 different non-classical EGFR mutations 86% CNS response rate (brain mets) …

Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …

Alpha Cognition (ACOG: Nasdaq) Undervaluation Thesis -A $6 Stock (EV: $57M) That's Being Valued on Trailing Revs Instead of 2026 Reality Alpha Cognition (ACOG) Undervaluation: The Market Is Pricing the Wrong Year Price: \\\~$6.00 Market cap: \\\~$130M Cash: \\\~$73M Enterprise value: $57M FDA Approved Alzheimer's Drug ZUNVEYL (9th drug to …

Alpha Cognition (ACOG: Nasdaq) Undervaluation Thesis -A $6 Stock (EV: $57M) That's Being Valued on Trailing Revs Instead of 2026 Reality Alpha Cognition (ACOG) Undervaluation: The Market Is Pricing the Wrong Year Price: \\\~$6.00 Market cap: \\\~$130M Cash: \\\~$73M Enterprise value: $57M FDA Approved Alzheimer's Drug ZUNVEYL (9th drug to …

LEXX – BIG Pharma-Backed Tech - Billion-Dollar Potential Lexaria’s DehydraTECH is a drug-delivery upgrade. It takes an existing drug molecule and binds it with specific lipids, then processes it so the drug: -absorbs faster -absorbs more efficiently -avoids some first-pass liver destruction Think of it as: Make the same drug …

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL^(™), a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that …

Most Asymmetric Opportunity in Biotech (and the whole market?) $GANX **It’s not often that an investment opportunity comes along with the asymmetric upside and limited downside that GANX has IMO, and in such a short timeline**. The problem is that most investors can’t take a casual glance at the company …

Newron Pharmaceuticals- Again Up 12% - more to come🚀🚀🚀 ​ 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), …

PSTV, insurance coverage deal [https://www.globenewswire.com/news-release/2025/11/20/3191797/0/en/Plus-Therapeutics-Secures-National-Coverage-Agreement-with-Humana-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html](https://www.globenewswire.com/news-release/2025/11/20/3191797/0/en/Plus-Therapeutics-Secures-National-Coverage-Agreement-with-Humana-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html) Nice bullish deal here for one of their pipelines getting covered by Humana.

Great news for PSTV $PSTV Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer https://www.stocktitan.net/news/PSTV/plus-therapeutics-secures-national-coverage-agreement-with-humana-iu6giw4somvi.html

Newron Pharmaceuticals: Still under investors radar 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), and the massive valuation …

Newron Pharmaceuticals- Strong Buy Recommendation 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), and the massive valuation gap …